Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.
AUTOR(ES)
Perfect, J R
RESUMO
We studied the pharmacokinetics and in vivo antifungal action of SCH39304, a new antifungal azole compound, in rabbits. It crossed the blood-cerebrospinal fluid barrier in the presence or absence of meningeal inflammation, reaching approximately 60% of the simultaneous concentrations in serum. In the treatment of experimental cryptococcal meningitis, SCH39304 was as effective as fluconazole in reducing yeast counts in the subarachnoid space. SCH39304 and fluconazole both were highly effective against candida endophthalmitis, sterilizing the vitreous humor and the choroid and retina. SCH39304 suppressed candida endocarditis and reduced yeast counts in the kidney at all doses tested. SCH39304 was effective in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. Further investigations in humans are warranted.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=172747Documentos Relacionados
- Treatment of murine coccidioidal meningitis with SCH39304.
- Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination.
- SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits.
- Treatment of experimental cryptococcosis with SCH 39304 and fluconazole.
- Comparison of SCH 39304 and its isomers, RR 42427 and SS 42426, for treatment of murine cryptococcal and coccidioidal meningitis.
